These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. The effect of bromocriptine in patients with benign prostatic hypertrophy. Farrar DJ; Pryor JS Br J Urol; 1976 Feb; 48(1):73-5. PubMed ID: 57815 [TBL] [Abstract][Full Text] [Related]
83. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study]. Montastruc JL; Rascol O; Rascol A Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588 [TBL] [Abstract][Full Text] [Related]
85. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P; Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842 [TBL] [Abstract][Full Text] [Related]
86. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease. Lieberman AN; Gopinathan G; Pasternack P; Goldstein M Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521 [No Abstract] [Full Text] [Related]
87. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group. J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):77-82. PubMed ID: 2651567 [TBL] [Abstract][Full Text] [Related]
88. The antiparkinsonian efficacy of bromocriptine. Lieberman A; Zolfaghari M; Boal D; Hassouri H; Vogel B; Battista A; Fuxe K; Goldstein M Neurology; 1976 May; 26(5):405-9. PubMed ID: 817221 [TBL] [Abstract][Full Text] [Related]